Document Detail

Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy.
MedLine Citation:
PMID:  21279982     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To report the anatomic and functional outcome of intravitreal bevacizumab (IVB) to treat choroidal neovascularization (CNV) following photodynamic therapy (PDT) to treat recurrent central serous choroidopathy (CSC).
METHODS: This was an interventional case report in which verteporfin PDT was performed in a case of recurrent CSC.
RESULTS: Following PDT, the patient developed juxtafoveal CNV that was later treated by IVB, achieving CNV closure and recovery of visual acuity.
CONCLUSIONS: Photodynamic therapy is a useful therapy to treat recurrent CSC, though it may be associated with potentially severe complications such as CNV. Intravitreal bevacizumab seems a good alternative treatment in the management of this condition.
Javier A Montero; José M Ruiz-Moreno; Marta Fernandez-Muñoz
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  European journal of ophthalmology     Volume:  21     ISSN:  1724-6016     ISO Abbreviation:  Eur J Ophthalmol     Publication Date:    2011 Jul-Aug
Date Detail:
Created Date:  2011-12-13     Completed Date:  2012-03-02     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9110772     Medline TA:  Eur J Ophthalmol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  503-5     Citation Subset:  IM    
Vitreo-Retinal Unit, Alicante Institute of Ophthalmology, VISSUM, Alicante, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Central Serous Chorioretinopathy / drug therapy*,  physiopathology
Choroidal Neovascularization / drug therapy*,  etiology,  physiopathology
Combined Modality Therapy
Fluorescein Angiography
Intravitreal Injections
Photochemotherapy / adverse effects*
Photosensitizing Agents / therapeutic use
Porphyrins / therapeutic use
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Photosensitizing Agents; 0/Porphyrins; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 129497-78-5/verteporfin; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Retinitis pigmentosa inversa with unilateral high myopia with fellow eye optic disc pitting.
Next Document:  An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, pla...